FDA Doxycycline Shortage: Mayne Pharma Discontinuation Alert

FDA Reports Doxycycline Hyclate Tablet Shortage: Discontinuation Announced

On January 7, 2025, FDA updated its Drug Shortages Database to reflect a shortage of doxycycline hyclate delayed-release tablets (75 mg and 150 mg), manufactured by Mayne Pharma. The manufacturer has permanently discontinued production of both strengths, removing a significant antibiotic product from the U.S. pharmaceutical supply chain. Wholesale drug distributors holding inventory of these NDCs must adjust allocation strategies and communicate availability constraints to downstream customers.

Regulatory Context

FDA maintains the Drug Shortages Database under authority granted by the Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012. The agency tracks shortages of medically necessary drugs where a supply disruption would create significant patient harm. Under 21 U.S.C. § 356c, manufacturers must notify FDA at least six months before discontinuing a drug product that is life-supporting, life-sustaining, or intended for use in the prevention or treatment of a debilitating disease or condition.

Doxycycline hyclate is a tetracycline antibiotic indicated for bacterial infections including respiratory tract infections, skin infections, and certain sexually transmitted infections. While multiple manufacturers produce generic doxycycline formulations, the delayed-release presentation addresses gastrointestinal tolerability issues common with immediate-release versions. Discontinuation of this formulation creates a gap in available therapeutic options for patients who cannot tolerate standard doxycycline products.

Manufacturer Discontinuation Details

Mayne Pharma has permanently discontinued the following presentations:

• Doxycycline hyclate delayed-release tablets, 75 mg (NDC 51862-584)
• Doxycycline hyclate delayed-release tablets, 150 mg (NDC 51862-585)

FDA's shortage designation status: Shortage

Estimated resolution: Discontinued — no resupply expected

Reason provided: Discontinuation

Unlike temporary supply interruptions caused by manufacturing delays or API shortages, this is a permanent market exit. Mayne Pharma has not announced plans to license the formulation to another manufacturer or transfer the NDA to a third party. Remaining inventory in the distribution channel represents the final available supply of this specific product configuration.

Impact on Wholesale Drug Distributors

Wholesale drug distributors face three immediate operational challenges:

1. Inventory allocation and rationing

Distributors holding existing stock must implement allocation protocols to prevent hoarding or speculative purchasing. Historical dispensing patterns, customer classification (hospital vs. retail pharmacy), and contractual obligations determine allocation priorities. Without active resupply from the manufacturer, distributors cannot replenish depleted inventory through normal ordering channels.

2. Customer communication and alternative sourcing

Distributors must proactively notify downstream customers (pharmacies, hospitals, clinics) of the discontinuation and limited remaining stock. This includes providing information on therapeutically equivalent alternatives, primarily immediate-release doxycycline hyclate products from other manufacturers. Procurement teams at customer facilities may require documentation of the shortage for their own compliance and patient care continuity processes.

3. Gray market risk mitigation

Drug shortages historically create conditions for gray market activity, where unauthorized distributors offer scarce products at inflated prices. DSCSA transaction requirements and state licensure laws restrict the sale of prescription drugs to authorized trading partners. Distributors must verify the licensure status of any entity offering doxycycline hyclate delayed-release tablets and reject offers from unlicensed sources, regardless of price or claimed availability.

What ColdChainCheck Data Shows

ColdChainCheck tracks 1,275 wholesale drug distributors and 3PLs across 51 jurisdictions. Of these entities, 1,234 hold active FDA establishment registration — a baseline requirement for handling prescription drug products like doxycycline hyclate. During shortage conditions, the compliance posture of trading partners becomes operationally critical. Entities with lower compliance scores (38 entities in the "Poor" tier, 9 in "Minimal") may lack the infrastructure to handle allocation protocols, substitution documentation, or gray market detection that shortage management requires.

The average compliance score in the directory is 51/100, placing most entities in the "Fair" tier (919 entities). This reflects adequate state licensure coverage but limited verification of higher-tier signals like NABP accreditation (only 63 entities hold VAWD accreditation). During shortages, NABP-accredited distributors typically demonstrate more robust supply chain controls and transaction documentation practices — relevant when verifying the provenance of remaining doxycycline inventory.

Practical Steps for QA and Procurement Teams

Verify distributor licensure before sourcing alternatives

Use the ColdChainCheck directory to confirm that any entity offering doxycycline hyclate delayed-release tablets — or therapeutic alternatives — holds active state licenses in your jurisdiction. Filter by state and check the entity's compliance score breakdown. Entities claiming to have remaining inventory should show FDA registration and current licensure. Unlicensed entities offering scarce drugs are a regulatory red flag.

Document trading partner compliance for audit trails

If your organization switches to a new doxycycline supplier due to the Mayne Pharma discontinuation, document the compliance verification process. Export the entity's ColdChainCheck profile (compliance score, license list, NABP status) as part of your vendor qualification file. Auditors reviewing shortage-period procurement decisions expect documented due diligence on alternative sources.

Monitor for related shortage developments

Antibiotic shortages frequently cluster due to shared API suppliers or manufacturing capacity constraints. ColdChainCheck does not predict shortages, but the directory's FDA recall tracking identifies entities with recent quality issues. The compliance guides section covers DSCSA transaction requirements and state-specific wholesaler licensure rules relevant to shortage-period sourcing decisions.

Cross-reference NABP accreditation for high-risk transactions

Of the 1,275 tracked entities, only 63 hold NABP accreditation. During shortages, prioritize NABP-accredited distributors for alternative sourcing. These entities undergo annual compliance audits covering pedigree documentation, storage conditions, and transaction verification — the same controls that mitigate gray market risk during supply disruptions.

Disclaimer: This article provides informational content based on publicly available FDA data as of the publication date. It is not legal or regulatory advice. Verify all compliance requirements with qualified legal counsel and the relevant regulatory authorities.